These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 28195646)

  • 1. NS1209/SPD 502, A Novel Selective AMPA Antagonist for Stroke, Neuropathic Pain or Epilepsy? Drug Development Lessons Learned.
    Keppel Hesselink JM
    Drug Dev Res; 2017 Mar; 78(2):75-80. PubMed ID: 28195646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study.
    Gormsen L; Finnerup NB; Almqvist PM; Jensen TS
    Anesth Analg; 2009 Apr; 108(4):1311-9. PubMed ID: 19299805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic window of opportunity for the neuroprotective effect of valproate versus the competitive AMPA receptor antagonist NS1209 following status epilepticus in rats.
    Langer M; Brandt C; Zellinger C; Löscher W
    Neuropharmacology; 2011; 61(5-6):1033-47. PubMed ID: 21736883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioural effects of the novel AMPA/GluR5 selective receptor antagonist NS1209 after systemic administration in animal models of experimental pain.
    Blackburn-Munro G; Bomholt SF; Erichsen HK
    Neuropharmacology; 2004 Sep; 47(3):351-62. PubMed ID: 15275824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, randomized, multicentre trial for the treatment of refractory status epilepticus; experiences from evaluating the effect of the novel drug candidate, NS1209.
    Sabers A; Wolf P; Møller A; Rysgaard K; Ben-Menachem E
    Epilepsy Res; 2013 Sep; 106(1-2):292-5. PubMed ID: 23623849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity.
    Nielsen EO; Varming T; Mathiesen C; Jensen LH; Moller A; Gouliaev AH; Wätjen F; Drejer J
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1492-501. PubMed ID: 10336544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of novel AMPA antagonist, NS1209, on status epilepticus. An experimental study in rat.
    Pitkänen A; Mathiesen C; Rønn LC; Møller A; Nissinen J
    Epilepsy Res; 2007 Apr; 74(1):45-54. PubMed ID: 17289347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Grey matter and white matter ischemic damage is reduced by the competitive AMPA receptor antagonist, SPD 502.
    McCracken E; Fowler JH; Dewar D; Morrison S; McCulloch J
    J Cereb Blood Flow Metab; 2002 Sep; 22(9):1090-7. PubMed ID: 12218414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The structure of a mixed GluR2 ligand-binding core dimer in complex with (S)-glutamate and the antagonist (S)-NS1209.
    Kasper C; Pickering DS; Mirza O; Olsen L; Kristensen AS; Greenwood JR; Liljefors T; Schousboe A; Wätjen F; Gajhede M; Sigurskjold BW; Kastrup JS
    J Mol Biol; 2006 Apr; 357(4):1184-201. PubMed ID: 16483599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irampanel Boehringer Ingelheim.
    Feigin V
    Curr Opin Investig Drugs; 2002 Jun; 3(6):908-10. PubMed ID: 12137411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of anti-absence effects of ethosuximide by low doses of a noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist in a genetic animal model of absence epilepsy.
    Russo E; Citraro R; De Fazio S; Marra R; Gitto R; Chimirri A; De Sarro G; Di Paola ED
    Epilepsy Behav; 2008 Aug; 13(2):295-9. PubMed ID: 18514580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of perampanel in epilepsy.
    Satlin A; Kramer LD; Laurenza A
    Acta Neurol Scand Suppl; 2013; (197):3-8. PubMed ID: 23480150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective small molecule angiotensin II type 2 receptor antagonists for neuropathic pain: preclinical and clinical studies.
    Smith MT; Anand P; Rice ASC
    Pain; 2016 Feb; 157 Suppl 1():S33-S41. PubMed ID: 26785154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models.
    Zwart R; Sher E; Ping X; Jin X; Sims JR; Chappell AS; Gleason SD; Hahn PJ; Gardinier K; Gernert DL; Hobbs J; Smith JL; Valli SN; Witkin JM
    J Pharmacol Exp Ther; 2014 Oct; 351(1):124-33. PubMed ID: 25027316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New AMPA antagonists in epilepsy.
    Russo E; Gitto R; Citraro R; Chimirri A; De Sarro G
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1371-89. PubMed ID: 22788917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AMPA receptors in epilepsy and as targets for antiepileptic drugs.
    Rogawski MA; Donevan SD
    Adv Neurol; 1999; 79():947-63. PubMed ID: 10514878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy.
    Faught E
    Expert Opin Investig Drugs; 2014 Jan; 23(1):107-13. PubMed ID: 24147649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate.
    Perucca E
    Epilepsia; 2009 Dec; 50 Suppl 12():49-50. PubMed ID: 19941524
    [No Abstract]   [Full Text] [Related]  

  • 19. AMPA receptor inhibitors for the treatment of epilepsy: the role of perampanel.
    Zaccara G; Giovannelli F; Cincotta M; Iudice A
    Expert Rev Neurother; 2013 Jun; 13(6):647-55. PubMed ID: 23739002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress on the issue of excitotoxic injury modification vs. real neuroprotection; implications for post-traumatic epilepsy.
    Sloviter RS
    Neuropharmacology; 2011; 61(5-6):1048-50. PubMed ID: 21839755
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.